Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 106 articles:
HTML format
Text format



Single Articles


    May 2019
  1. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    PubMed     Text format    


  2. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    PubMed     Text format    


  3. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    PubMed     Text format     Abstract available


  4. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    PubMed     Text format    


    April 2019
  5. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed     Text format    


    March 2019
  6. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    PubMed     Text format    


  7. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    


  8. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    


  9. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    


  10. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    PubMed     Text format     Abstract available


  11. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    PubMed     Text format    


  12. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    PubMed     Text format     Abstract available


    February 2019
  13. KIMURA T
    Can ultra-thin strut drug-eluting stents improve outcomes?
    Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
    PubMed     Text format    


  14. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
    Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
    Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
    PubMed     Text format     Abstract available


  15. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
    The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
    Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
    PubMed     Text format    


    December 2018
  16. NASLUND U, Ng N, Lundgren A, Fharm E, et al
    Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
    Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
    PubMed     Text format     Abstract available


    November 2018
  17. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available


    October 2018
  18. COLOMBO A, Giannini F
    Encouraging data from ABSORB IV pave the way to new scaffolds.
    Lancet. 2018;392:1490-1491.
    PubMed     Text format    


  19. STONE GW, Ellis SG, Gori T, Metzger DC, et al
    Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Lancet. 2018;392:1530-1540.
    PubMed     Text format     Abstract available


  20. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
    PubMed     Text format     Abstract available


  21. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    


  22. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available


    September 2018
  23. CAMENZIND E, Popovic B
    Are all drug-eluting stents created equal?
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
    PubMed     Text format    


  24. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
    Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
    PubMed     Text format     Abstract available


  25. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
    Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
    PubMed     Text format     Abstract available


  26. HO HH, Ong PJL
    BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
    Lancet. 2018;392:802-804.
    PubMed     Text format    


  27. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
    Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
    Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
    PubMed     Text format     Abstract available


  28. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
    Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Lancet. 2018;392:737-746.
    PubMed     Text format     Abstract available


    August 2018
  29. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
    Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
    PubMed     Text format     Abstract available


  30. CAPODANNO D, Angiolillo DJ
    Aspirin for primary prevention of cardiovascular disease.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
    PubMed     Text format    


  31. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
    Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
    PubMed     Text format     Abstract available


  32. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
    Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
    PubMed     Text format     Abstract available


  33. ANGIOLILLO DJ
    Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
    PubMed     Text format    


  34. BLANKENBERG S, Neumann JT, Westermann D
    Diagnosing myocardial infarction: a highly sensitive issue.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
    PubMed     Text format    


  35. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
    PubMed     Text format     Abstract available


  36. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
    High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
    PubMed     Text format     Abstract available


  37. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
    Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
    PubMed     Text format     Abstract available


  38. MAHABADI AA, Rassaf T
    Imaging of coronary inflammation for cardiovascular risk prediction.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
    PubMed     Text format    


  39. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
    Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
    Lancet. 2018;392:496-506.
    PubMed     Text format     Abstract available


  40. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available


    July 2018
  41. THEKEN KN, Grosser T
    Weight-adjusted aspirin for cardiovascular prevention.
    Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
    PubMed     Text format    


  42. DOWLING C, Firoozi S, Brecker S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    


  43. FRANCIS DP, Al-Lamee R
    Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
    Lancet. 2018;392:28-30.
    PubMed     Text format    


  44. BANNING A, Redwood S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    


  45. BAUER A, Rizas KD, Massberg S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27.
    PubMed     Text format    


  46. REED GW, Kapadia SR
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27-28.
    PubMed     Text format    


  47. POCOCK SJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26-27.
    PubMed     Text format    


  48. BARAKAT MF, Simitsis P
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26.
    PubMed     Text format    


  49. TU T, Liu Q, Hu X, Zhou S, et al
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    


  50. MUTHALALY RG, Nerlekar N, Brown AJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25-26.
    PubMed     Text format    


  51. DEGRELL P, Picard F, Varenne O
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    


    June 2018
  52. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    


  53. MARIATHAS M, Curzen N
    Troponin assays: developing indications.
    Lancet. 2018;391:2398-2399.
    PubMed     Text format    


  54. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
    Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet. 2018;391:2325-2334.
    PubMed     Text format     Abstract available


  55. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
    Consequence of reimbursement policy alteration for urgent PCI in Japan.
    Lancet. 2018;391:2208-2209.
    PubMed     Text format    


    May 2018
  56. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
    Daytime variations in perioperative myocardial injury - Authors' reply.
    Lancet. 2018;391:2106.
    PubMed     Text format    


  57. SPADACCIO C, Dalby M, Danton MHD
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2105-2106.
    PubMed     Text format    


  58. LUCCHINETTI E, Zaugg M
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104-2105.
    PubMed     Text format    


  59. BARTMAN CM, Oyama Y, Eckle T
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104.
    PubMed     Text format    


  60. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    PubMed     Text format     Abstract available


  61. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    PubMed     Text format     Abstract available


  62. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    PubMed     Text format    


    April 2018
  63. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    PubMed     Text format    


  64. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    PubMed     Text format    


  65. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    PubMed     Text format    


  66. CAO XP, Tan CC, Yu JT
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679-1680.
    PubMed     Text format    


  67. CARBONE S, Billingsley H, Abbate A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679.
    PubMed     Text format    


  68. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    PubMed     Text format    


  69. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    PubMed     Text format    


  70. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    PubMed     Text format    


  71. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    


  72. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed     Text format    


  73. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    PubMed     Text format    


  74. CHU DK, Kim LH, Young PJ, Zamiri N, et al
    Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
    Lancet. 2018;391:1693-1705.
    PubMed     Text format     Abstract available


    March 2018
  75. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    PubMed     Text format    


  76. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    PubMed     Text format    


  77. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    PubMed     Text format    


  78. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    PubMed     Text format    


  79. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    PubMed     Text format     Abstract available


    February 2018
  80. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    PubMed     Text format     Abstract available


  81. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed     Text format    


  82. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    


  83. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    


    January 2018
  84. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    PubMed     Text format    


  85. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    PubMed     Text format    


  86. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
    Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:219-229.
    PubMed     Text format     Abstract available


  87. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    PubMed     Text format    


  88. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    PubMed     Text format    


  89. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    PubMed     Text format    


    December 2017
  90. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    PubMed     Text format    


  91. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    PubMed     Text format    


  92. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    PubMed     Text format    


  93. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available


  94. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    PubMed     Text format     Abstract available


    November 2017
  95. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    PubMed     Text format     Abstract available


  96. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    PubMed     Text format     Abstract available


  97. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    PubMed     Text format     Abstract available


  98. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    PubMed     Text format     Abstract available


    October 2017
  99. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    PubMed     Text format     Abstract available


  100. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    PubMed     Text format     Abstract available


  101. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    PubMed     Text format    


    September 2017
  102. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    PubMed     Text format     Abstract available


    August 2017
  103. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    PubMed     Text format     Abstract available


  104. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Text format     Abstract available


  105. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    PubMed     Text format     Abstract available


    April 2017
  106. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: